Beigene LtdNASDAQ:BGNE
- LAST PRICE208.4200
- TODAY'S CHANGE (%)4.2100 (2.0616%)
- Bid / Lots208.2400/ 8
- Ask / Lots208.7000/ 8
- Open / Previous Close204.8600 / 204.2100
- Day Range
- 52 Week Range
- Volume105,669
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BGNE |
|---|---|---|
| 09:32 ET | 1908 | 204.86 |
| 09:33 ET | 208 | 205.685 |
| 09:35 ET | 610 | 206.51 |
| 09:37 ET | 700 | 207.51 |
| 09:39 ET | 600 | 207.34 |
| 09:42 ET | 100 | 206.96 |
| 09:44 ET | 300 | 207.83 |
| 09:46 ET | 100 | 207.7 |
| 09:48 ET | 1022 | 207.255 |
| 09:50 ET | 800 | 207.255 |
| 09:51 ET | 2517 | 206.975 |
| 09:53 ET | 785 | 207.365 |
| 09:57 ET | 200 | 207.64 |
| 10:00 ET | 100 | 207.415 |
| 10:04 ET | 700 | 208.045 |
| 10:06 ET | 200 | 208.07 |
| 10:08 ET | 856 | 207.985 |
| 10:09 ET | 100 | 208 |
| 10:11 ET | 600 | 207.71 |
| 10:13 ET | 600 | 207.895 |
| 10:15 ET | 500 | 207.895 |
| 10:18 ET | 150 | 207.867 |
| 10:20 ET | 600 | 207.55 |
| 10:22 ET | 100 | 207.91 |
| 10:24 ET | 300 | 208.46 |
| 10:26 ET | 100 | 208.015 |
| 10:29 ET | 400 | 208.185 |
| 10:33 ET | 100 | 208.6 |
| 10:40 ET | 100 | 208.68 |
| 10:42 ET | 100 | 208.73 |
| 10:47 ET | 6578 | 208.18 |
| 10:49 ET | 100 | 208.12 |
| 10:51 ET | 100 | 208.445 |
| 10:54 ET | 300 | 208.46 |
| 10:56 ET | 400 | 209.04 |
| 10:58 ET | 800 | 209.78 |
| 11:00 ET | 183 | 209.745 |
| 11:12 ET | 200 | 210.31 |
| 11:14 ET | 157 | 209.875 |
| 11:23 ET | 300 | 209.885 |
| 11:25 ET | 559 | 209.78 |
| 11:27 ET | 100 | 209.89 |
| 11:30 ET | 700 | 210.165 |
| 11:34 ET | 100 | 210.39 |
| 11:36 ET | 700 | 209.8122 |
| 11:39 ET | 503 | 209.8 |
| 11:45 ET | 400 | 208.565 |
| 11:50 ET | 100 | 208.62 |
| 11:52 ET | 100 | 209.04 |
| 11:56 ET | 129 | 208.945 |
| 11:59 ET | 554 | 208.68 |
| 12:03 ET | 200 | 208.925 |
| 12:06 ET | 600 | 209.18 |
| 12:12 ET | 100 | 209.23 |
| 12:17 ET | 200 | 209.29 |
| 12:21 ET | 100 | 209.52 |
| 12:24 ET | 800 | 209.51 |
| 12:26 ET | 494 | 209.66 |
| 12:33 ET | 800 | 209.9 |
| 12:35 ET | 138 | 210.01 |
| 12:39 ET | 100 | 210.28 |
| 12:48 ET | 300 | 210.07 |
| 12:51 ET | 1000 | 209.84 |
| 12:53 ET | 400 | 210.09 |
| 12:55 ET | 100 | 210.02 |
| 01:02 ET | 1900 | 209.98 |
| 01:04 ET | 100 | 210.025 |
| 01:08 ET | 219 | 210.0716 |
| 01:09 ET | 300 | 209.73 |
| 01:13 ET | 300 | 209.89 |
| 01:22 ET | 163 | 210.1124 |
| 01:31 ET | 100 | 210.0947 |
| 01:36 ET | 1686 | 210.07 |
| 02:00 ET | 1600 | 209.93 |
| 02:03 ET | 551 | 209.53 |
| 02:05 ET | 300 | 208.98 |
| 02:07 ET | 100 | 209.03 |
| 02:12 ET | 400 | 209.06 |
| 02:27 ET | 100 | 209.11 |
| 02:32 ET | 200 | 208.9 |
| 02:39 ET | 100 | 208.8 |
| 02:48 ET | 200 | 209.14 |
| 02:54 ET | 500 | 209.745 |
| 02:56 ET | 100 | 210.08 |
| 02:59 ET | 400 | 209.65 |
| 03:03 ET | 603 | 209.275 |
| 03:08 ET | 100 | 209.265 |
| 03:17 ET | 1340 | 209.195 |
| 03:24 ET | 1063 | 208.63 |
| 03:26 ET | 900 | 208.6 |
| 03:28 ET | 1514 | 208.45 |
| 03:32 ET | 7224 | 208.36 |
| 03:33 ET | 700 | 208.42 |
Oct 28, 2024
BeiGene Mourns Death of Beloved Board Member Donald Glazer, from 6:00AM ET on Monday Oct 28, 2024 by Dow Jones
6:00AM ET on Monday Oct 28, 2024 by Dow Jones
Oct 22, 2024
DJ Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment, from 2:24PM ET on Tuesday Oct 22, 2024 by Dow Jones
2:24PM ET on Tuesday Oct 22, 2024 by Dow JonesDJ BeiGene Is Maintained at Overweight by JP Morgan, from 1:05PM ET on Tuesday Oct 22, 2024 by Dow Jones
1:05PM ET on Tuesday Oct 22, 2024 by Dow Jones
Oct 21, 2024
Oct 16, 2024
BeiGene Highlights Waldenstr m's Macroglobulinemia Innovation at IWWM 2024, from 6:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
6:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beigene Ltd | 22.8B | -41.1x | --- |
United Therapeutics Corp | 16.6B | 16.5x | +8.22% |
Genmab A/S | 15.0B | 18.7x | +20.61% |
Exact Sciences Corp | 12.9B | -74.2x | --- |
BioMarin Pharmaceutical Inc | 12.7B | 39.8x | --- |
Neurocrine Biosciences Inc | 12.3B | 32.1x | +62.04% |
Company Information
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Contact Information
- Headquarters
- C/O Mourant Governance Services (Cayman) 94 Solaris Avenue, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108
- Phone
- 345-949-4123
- Fax
- ---
Executives
- Co-Founder, Executive Chairman of the Board, Chief Executive Officer
- John Oyler
- President, Chief Operating Officer, General Manager - China
- Xiaobin Wu
- Co-Founder, Non-Executive Director
- Xiaodong Wang
- Chief Financial Officer
- Aaron Rosenberg
- General Manager, North America
- Matthew Shaulis
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $22.8B |
|---|---|
Revenue (TTM) | $3.1B |
Shares Outstanding | 106.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $-5.08 |
Book Value | $36.95 |
P/E Ratio | -41.1x |
Price/Sales (TTM) | 7.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16.90% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
